The answer to yesterday’s #ClinicalChallenge question is: D. A recent meta-analysis described the results of 25 clinical trials including over 10,000 patients with rheumatoid arthritis that compared biosimilar tumor necrosis factor (TNF)-alpha inhibitors with their reference biologic products, including infliximab, etanercept, and adalimumab. Biosimilars were equivalent to reference biologics in terms of disease activity (as measured by the American College of Rheumatology 20 response) and patient function (as measured by the Health Assessment Questionnaire Disability Index scores). Rheumatoid arthritis patients managed with TNF inhibitors can be reassured that biosimilars are as effective as bio-originators for the management of their disease. View the related What's New topic in #UpToDate: https://ow.ly/GLeB50Q7eVH #rheumatology #MedEd
